Acute myocardial infarction had generally been considered to be the result of thrombotic occlusion of a major extramural coronary revealed a high incidence (88.9%) of coronary thrombi.9
Pathogenesis of Acute Myocardial Infarction
Novel Regulatory Systems 9 with only subendocardial necrosis, and in 2 (8%) of 24 who died suddenly. On the basis of their own data and of the literature, which reported the frequency of coronary thrombosis in fatal acute myocardial infarction as ranging from 21% to 91%, they claimed that coronary thrombi are consequences rather than causes of acute myocardial infarction. Similar conclusions were reached by other investigators. [2] [3] [4] [5] In a workshop on the role of coronary thrombosis in the pathogenesis of acute myocardial infarction, no unanimous conclusion was obtained as to whether the thrombus precedes infarction as a primary lesion or follows infarction as a secondary effect. The report of the workshop stated that although most evidence continues to affirm myocardial infarction to be caused by thrombotic occlusion of a coronary artery, the idea of coronary thrombosis as a secondary event after infarction is also provocative and deserves serious consideration. 6 Most of our knowledge of the lesions associated with transmural infarction before 1980 was derived from autopsy studies. These studies were performed in patients who died days to weeks after the infarction or in patients who died suddenly (less than 6 hours after the onset of symptoms). It is generally accepted that postmortem studies on victims of sudden death often reveal multivessel coronary atherosclerosis but only rarely evidence of an acute coronary event or myocardial necrosis. 78 However, an autopsy study in which the time interval between the onset of symptoms and death was less than 24 hours and was accurately ascertained revealed a high incidence (88.9%) of coronary thrombi. 9 The frequency of coronary thrombi decreased with the time after the onset of myocardial infarction.
During the past decade, the increased use of coronary arteriography has enabled us to explore the morphology of coronary arteries within 4 to 6 hours after the onset of infarction, which was rarely possible in previous (postmortem) studies. DeWood et al10 reported that total coronary occlusion was observed in 110 of 126 patients (87%) evaluated within 4 hours after the onset of symptoms: this proportion decreased significantly to 65% in patients examined 12 to 24 hours after the onset of symptoms. With the development of thrombolytic therapy, the general consensus today is that thrombotic occlusion of a coronary artery is demonstrable in 80% to 95% of patients if coronary arteriography is performed during the early hours after the onset of myocardial infarction.9"1112 Thus, the controversy, particularly among pathologists, as to whether coronary artery thrombi are the cause or the result of acute myocardial infarction has been resolved by the demonstration by coronary arteriography of thrombotic coronary occlusion in the majority of patients within 4 to 6 hours after myocardial infarction.
Rupture of Coronary Atheromatous Plaque and Acute Myocardial Infarction
On the basis of the postmortem angiographic and histopathologic correlations described by Levin and Fallon,13 Ambrose et al14 stated that an asymmetric narrowing of a coronary artery in the form of a convex intraluminal obstruction with a narrow neck or irregular borders (or both) might represent a ruptured atherosclerotic plaque with or without a superimposed, partially occlusive intraluminal thrombus. These angiographic findings were common in the majority of patients with unstable angina at high risk for a subsequent coronary event.14 Irregular narrowing and a filling defect on coronary arteriography were associated with rupture and hemorrhage of the atheromatous plaque in patients who died a few days after selective intracoronary thrombolytic therapy. 15 It can now be generally appreciated that there are three pathological hallmarks in the infarct-related coronary artery at the site of acute myocardial infarction: ruptured lipid-rich atheromatous plaque, intraplaque hemorrhage, and intraluminal thrombus (Fig 1) creased TXA2 production and augmented platelet aggregability during acute myocardial ischemic events. [32] [33] [34] Intracoronary thrombolysis treatment since the 1980s has also provided us with a unique opportunity to study the role and genesis of intracoronary thrombus formation in acute myocardial infarction. Moreover, among intracoronary thrombolysis patients, it is not rare to encounter a case in which the coronary artery, once recanalized by the intracoronary infusion of thrombolytic agents, is immediately reoccluded at the same site. The reoccluded coronary artery is again recanalized by a second intracoronary infusion of a thrombolytic agent.
In a study of eight patients, the plasma TXB2 level in the coronary sinus blood was elevated after recanalization of the occluded left anterior descending coronary artery by an intracoronary infusion of urokinase due to the wash-out effect of locally accumulated TXB2, and a further marked increase in the plasma TXB2 level in the coronary sinus blood was confirmed immediately after reocclusion of the once recanalized coronary artery (Fig  3) . 35 other is the PGI2 stabilizing factor, which stabilizes unstable PGI2 in the circulating blood and prolongs the biological half-life of PGI2. The prostacyclin synthesis stimulating factor is reported to be decreased in hemolytic uremic syndrome56 and sickle cell anemia57; the PGI2 stabilizing factor is decreased in thrombotic thrombocytopenic purpura59 and in ischemic stroke.61
In our laboratory, PGI2 synthesis stimulating factor was measured in blood samples obtained from the pulmonary artery or the peripheral vein in 7 patients aged 47 (Fig 5) .
Purification of Serum PGI2 Stabilizing Factor and Apolipoprotein A-I
The PGI2 stabilizing factor in serum was purified from human serum through column chromatography to a single protein with a molecular weight of 28 000 by SDS-PAGE in our laboratory.62 The NH2-terminal amino acid sequence (32 residues) was H2N-Asp-GluPro-Pro-Gln-Ser-Pro-Trp-Asp-Arg-Val-Lys-Asp-LeuAla-Thr-Val-Tyr-Val-Asp-Val-Leu-Lys-Asp-Ser-GlyArg-Asp-Tyr-Val-Ser-Gln, and the COOH-terminal (three residues) was HOOC-Gln-Thr-Asn. These sequences were identical to those of human apolipoprotein (Apo) A-I. 63 Comparison of the amino acid composition of PGI2 stabilizing factor with that of human Apo A-I also revealed strong similarities (Table 1) . Thus, we concluded that PGI2 stabilizing factor is identical to Apo A-I. 62 Albumin has long been claimed to bind to PGI2 and to prolong its half-life.64 66 We also confirmed the activity of PGI2 stabilizing factor in commercially available human albumin (Cohn fraction V albumin, Sigma). A contaminated band of Apo A-I was detected by SDS-PAGE with silver staining in the Cohn fraction V albumin. This contaminated band also was identified as Apo A-I by Western blotting. Purified albumin lost its PGI2 binding activity. 62 The activity of PGI2 stabilizing factor varies in parallel with the concentration of Apo A-I. Apo A-I is a major apolipoprotein of high-density lipoprotein (HDL). The activity of PGI2 stabilizing factor was lost when HDL was delipidated by ethanol-diethyl ether. Nascent HDL reconstituted from Apo A-I and the phospholipid revealed PGI2 stabilizing activity. Delipidated Apo A-I and delipidated nascent HDL showed no binding activity with (3H)-PGI2. Thus, an a-helix structure of Apo A-I appears to be necessary for the binding with PGI2. No (Table 2 ).73 However, there were no significant differences among the four groups of patients with coronary artery disease. Previously, Yui et a162 demonstrated clearly that PGI2 stabilizing activity was manifested only by Apo A-I with an a-helix structure occupying the surface of the HDL particle. Free (delipidated) Apo A-I could not stabilize PGI2. The amount of HDL-associated Apo A-I has been reported to be affected by the amount of Apo A-II, which has a greater affinity than Apo A-I for the HDL particle, and 2 mole of Apo A-II is able to displace 1 mole of Apo A-I from HDL particles quantitatively.7475 Until now, no consistent results were obtained on the levels of Apo A-II in patients with ischemic heart disease.6768,76-78 Our study showed that Apo A-Il levels were significantly lower in patients with stable angina pectoris, with unstable angina pectoris, and during the acute and subacute phases of myocardial infarction than in the age-matched control subjects (Table 2) . However, values of Apo A-Il in patients with unstable angina pectoris and during the acute phase of myocardial infarction were higher than those in patients with angina pectoris or the subacute phase of myocardial infarction. Aoyama et a173 demonstrated that after incubation of human serum HDL from normal fasting men with increasing amounts of Apo A-II, HDL-associated Apo A-I was displaced by Apo A-IL, and free Apo A-I was increased in parallel. PGI2 binding activity decreased with increasing concentrations of Apo A-Il (Fig 6) .
The regulatory factors involved in the synthesis and secretion of Apo A-Il are not fully understood yet. The pentapeptide of proapolipoprotein A-II is cleaved by the proapolipoprotein A-Il converting enzyme and then converted into mature apolipoprotein A-IL.79 This specific converting enzyme may play a key role in the synthesis of Apo A-IL.
The calculated HDL-associated Apo A-I levels80 were lower in the four groups of coronary artery disease than in the age-matched control subjects (Table 2) . Moreover, the HDL-associated Apo A-I levels in patients with unstable angina pectoris and during the acute phase of myocardial infarction were significantly lower than those in patients with stable angina pectoris and during the subacute phase of myocardial infarction and lowest among these groups, thus coinciding with the level of PGI2 stabilizing factor (Figs 5 and 7 ). In conclusion, HDL-associated Apo A-I, which is regulated by Apo A-Il, is able to stabilize PGI2 and appears to play an important role in the prevention of intracoronary thrombus formation in part through the stabilization of PGI2.
Endothelium-Derived Relaxing Factor and Purification of Nitric Oxide Synthase
Since the report of Furchgott and Zawadzki81 in 1980, endothelium-derived relaxing factor (EDRF) has been Based on the animal experiments showing the effect of nitric oxide (EDRF) on the protection against platelet aggregation and thrombus formation in endothelium-injured coronary arteries, the effect of L-arginine, the substrate for nitric oxide, on endothelium-dependent vasodilation of the coronary artery and on platelet aggregation has been studied recently in humans.
Intracoronary infusion of L-arginine did not affect acetylcholine-induced epicardial artery vasomotion but enhanced endothelium-dependent dilation of the coronary microvasculature in patients with hypercholesterolemia but not in normocholesterolemic patients with coronary artery disease and/or hypertension.110 Similarly, patients with depressed dilator response to acetylcholine, that is, those with endothelium dysfunction, had a greater response to L-arginine.11' In addition, infusion of L-arginine inhibited in vivo platelet function but it did not enhance the blunted inhibition of platelet aggregation with EDRF in atherosclerotic patients.1"2
One can expect that therapeutic applications of nitric oxide synthase and L-arginine may prevent thrombosis and vasoconstriction mediated by TXA2, serotonin, ADP, platelet-derived growth factor, and tissue factor at the sites of endothelial injury through promoting EDRF release from neighboring endothelial sites.
Summary and Conclusions
Rupture of the lipid-rich atheromatous plaque, intraplaque hemorrhage, and intraluminal thrombus are three pathological hallmarks most commonly recognized in the infarct-related coronary artery at the site of acute myocardial infarction. Rupture of the atheromatous plaque is closely related to but does not fully explain the genesis of occlusive intracoronary thrombus formation and thus the development of acute myocardial infarction. Besides a variety of hematologic disorders, one should emphasize the role of the plateletderived mediators that promote an environment where thrombosis and vasoconstriction occur, including TXA2, serotonin, ADP, platelet-derived growth factor, tissue factor, and the diminished availability of those natural endogenous substances that inhibit platelet Damage to the vascular endothelium at the time of atheromatous plaque rupture could provoke the breakdown of the exquisite homeostasis regulating platelet aggregation, prostaglandins, EDRF, and as yet unknown bioactive substances in the vessel wall, resulting in occlusive intracoronary thrombus formation and acute myocardial infarction. The present review clearly demonstrates the importance of the new discoveries to the regulatory systems in the vessel wall for intracoronary thrombus formation.
